Updated results of the PARP1/2 inhibitor pamiparib in combination with low-dose (Id) temozolomide (TMZ) in patients (pts) with locally advanced or metastatic solid tumours

Abstract

Background DNA damage caused by TMZ can sensitize tumors to PARP inhibitors. Pamiparib is an investigational PARP1/2 inhibitor that has shown PARP trapping activity, brain penetration, and synergistic cytotoxicity with ld TMZ in nonclinical studies. Methods This ongoing study consists of a dose-escalation phase (3+3 design) and a dose-expansion phase enrolling pts with gastric or small cell lung cancer (GC and SCLC). During dose escalation, pamiparib was administered at 60mg PO BID on days 1–28 and ld TMZ was given at escalating doses PO QD on days 1–7, 1–14, or 1–28 of 28-day cycles. During dose expansion, pts are being treated at the recommended phase 2 dose (RP2D); eligibility criteria in..